KRAS testing in metastatic colorectal cancer: Implications on the use of biologic agents

Clinical Colorectal Cancer

Volumn 8, Issue 3, 2009, Pages 135-140

  Bekaii Saab, Tanios ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bevacizumab; Cetuximab; Epidermal growth factor receptor; Panitumumab

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN INHIBITOR;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MONOTHERAPY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PHARMACOGENOMICS; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; TREATMENT RESPONSE;

EID: 69549122299     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.022     Document Type: Review

References (53)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Cohen DJ, Hochster HS. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 2007; 7(suppl 1):S21-7.
3. Reidy D, Saltz L. Targeted strategies in the treatment of metastatic colon cancer. J Natl Compr Canc Netw 2007; 5:983-990 (Pubitemid 350069533)
4. Díaz-Rubio E. Vascular endothelial growth factor inhibitors in colon cancer. Adv Exp Med Biol 2006; 587:251-275
5. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799 (Pubitemid 46606324)
6. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342 (Pubitemid 38702844)
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-1544
9. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30(suppl 7):3-14. (Pubitemid 36828623)
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345 (Pubitemid 38944402)
11. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664 (Pubitemid 46797944)
12. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007; 25(suppl):164s (Abstract 4000).
13. Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther 2007; 7:503-518 (Pubitemid 46681806)
14. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810 (Pubitemid 46211358)
15. Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. J Clin Oncol 2007; 25(suppl):184s (Abstract 4082)
16. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308. (Pubitemid 46480970)
17. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49:4682-4689 (Pubitemid 19213607)
18. Russo A, Bazan V, Aqnese V, et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005; 16(suppl 4):iv44-9. (Pubitemid 43084945)
19. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001; 85:692-696
20. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299-304. (Pubitemid 32112840)
21. Goodin S. Development of monoclonal antibodies for the treatment of colorectal cancer. Am J Health Syst Pharm 2008; 65(suppl 4):S3-7. (Pubitemid 351768723)
22. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26(suppl):178s (Abstract 4000).
23. Di Fiore F, Van Cutsem E, Laurent-Puig P, et al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. J Clin Oncol 2008; 26(suppl): (Abstract 403).
24. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-515 (Pubitemid 351325672)
25. Cohn AL, Smith DA, Neubauer MA, et al. Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI. J Clin Oncol 2008; 26(suppl):209s (Abstract 4127).
26. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379 (Pubitemid 351171687)
27. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-2648 (Pubitemid 46548951)
28. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-1169 (Pubitemid 46625066)
29. Finocchiaro G, Cappuzzo F, Jänne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2008; 26(suppl): (Abstract 4035).
30. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-3237 (Pubitemid 47325606)
31. Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7:184-190 (Pubitemid 351758148)
32. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-3995
33. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the firstline treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26(suppl):5s (Abstract 2).
34. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the CRYSTAL study: 1st-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab 71O E. Ann Oncol 2008; 19(suppl 8): viii44-viii46.
35. Punt CJ, Tol J, Rodenburg CJ, et al. Antonini. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26(suppl):180s (Abstract LBA4011).
36. Hecht JR, Mitchell EP, Baranda J, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): final efficacy and KRAS analyses. Presented at: the 2008 meeting of the American Society of Clinical Oncology: Gastrointestinal Symposium; January 25-27, 2008; Orlando, FL. Abstract 343.
37. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634
38. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
39. Hurwitz H, Rosen O, Yi J, et al. Clinical benefit of bevacizumab (BV) in metastatic colorectal cancer (MCRC) is independent of K-RAS mutation status: Exploratory analyses in a large placebo-controlled phase III study of previously untreated patients.Ann Oncol 2008; 19(suppl): Abstract O-035.
40. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97:981-989
41. Mitchell EP, Polikoff J, Badarinath S, et al. Analysis of K-RAS mutation status and EGFR gene copy number in the EXPLORE study: FOLFOX4 vs. FOLFOX4/cetuximab in previously treated metastatic colorectal cancer (mCRC). Presented at: the 2008 meeting of the American Society of Clinical Oncology: Gastrointestal Symposium; January 25-27, 2008; Orlando, FL. Abstract 306.
42. Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 2008; 26(suppl):178s (Abstract 4001).
43. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:427-432 (Pubitemid 46658516)
44. Mitchell EP, LaCouture ME, Shearer H, et al. A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis. J Clin Oncol 2008; 26(suppl): (Abstr 15007).
45. Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther 2007; 7:503-518 (Pubitemid 46681806)
46. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954 (Pubitemid 34716871)
47. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-280 (Pubitemid 43731112)
48. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25:3238-3245 (Pubitemid 47325607)
49. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-518
50. Scartozzi M, Falcone A, Pucci F, et al. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori 2006; 92:384-388 (Pubitemid 44861772)
51. Chong G, Dickson JL, Cunningham D, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005; 93:510-514 (Pubitemid 43079992)
52. Arce-Lara CE, Cataland S, Brady C, et al. A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS). J Clin Oncol 2007; 25(suppl): (Abstract 15167).
53. Folprecht G, Gruenberger T, Hartmann JT, et al. Randomized mylticenter study of cetuximab plus FOLFOX or plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal lver metastases (CELIM-STUDY).510 PD. Ann Oncol 2008; 19(supp):viii166-viii186.